However, by interrogating post-translational modifications and single cell analysis of the B-cell repertoire in MS blood and CSF, a recent landmark discovery identified an antibody (IgG) which targets GlialCAM in MS, especially when GlialCAM is post-translationally modified (Lanz et al., 2022). Here, HEPACAM is linked to myeloid sarcoma.